# Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF/ICSI

> **NCT07736261** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Ahmed Saad** · enrollment: 100 (estimated)

## Conditions studied

- Poor Ovarian Reserve
- Infertility (IVF Patients)

## Interventions

- **DRUG:** Drospirenone drug
- **DRUG:** Cetrorelix 0.25 mg

## Key facts

- **NCT ID:** NCT07736261
- **Lead sponsor:** Ahmed Saad
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2027-10
- **Final completion:** 2027-11
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07736261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07736261, "Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF/ICSI". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07736261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*